REVIEW article

Front. Immunol.

Sec. Molecular Innate Immunity

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1519465

This article is part of the Research TopicCommunity Series in the Role of Complement in Health and Disease: Volume IIView all 16 articles

Non-canonical extracellular complement pathways and the complosome paradigm in cancer: a scoping review

Provisionally accepted
  • 1Federal University of Paraná, Curitiba, Brazil
  • 2State University of Maringá, Maringá, Paraná, Brazil

The final, formatted version of the article will be published soon.

The Complement System (CS) comprises three catalytic pathways that can be activated by specific immune triggers. However, within the tumor microenvironment (TME), CS intracellular components, recently named as complosome, play roles that extend beyond the activation and regulation of its pathways. The interaction between TME elements and tumor cells alters the local immune response, leading to inflammation, cell proliferation, and tumor invasion. Our focus is on understanding the significance of complosome and non canonical pathways in cancer. In this scoping review, we analyzed 45 articles that discussed the various roles of CS components in carcinogenesis. Many CS components, including C1q, C3a-C3aR, C5a-C5aR, factor H, and properdin, some of them at the intracellular level, may play a dual role in tumor progression, demonstrating either anti-tumor or pro-tumor activity independent of complement pathway activation. The specific function of each component can influence both the type and stage of tumor cells. There is a notable lack of studies on the role of the lectin pathway in tumor development, and this knowledge gap must be addressed to fully understand the role of complosome in cancer. Nevertheless, the activation of CS and the roles of its components in complosome pathways are crucial steps in tumor development.• C1q has an anti-tumor role through the WWOX oncogene in breast and colon cancers• The C3a-C3aR and C5a-C5aR axis activate the PI3K/AKT and ERK/MEK1-2 pathways• Activation of C3 plays a negative regulatory role for the oncogene Her2• C5a promotes overexpression of the RGCC gene, which controls cell cycle progression • Properdin showed an antitumor function by regulating pro-apoptotic factors

Keywords: C3, c1q, C5, Cancer, complement system, Non-canonical activation pathway

Received: 29 Oct 2024; Accepted: 13 Mar 2025.

Copyright: © 2025 Oliveira-Toré, Moraes, Plácido, Signorini, Fontana, Godoy, Boldt and De Messias-Reason. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Camila de Freitas Oliveira-Toré, Federal University of Paraná, Curitiba, Brazil
Iara De Messias-Reason, Federal University of Paraná, Curitiba, Brazil

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Research integrity at Frontiers

94% of researchers rate our articles as excellent or good

Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


Find out more